The versatility and scalability of our technology and capabilities go beyond oncology, with potential cell and gene therapy applications in a wide range of indications. Our suite of next-generation gene engineering technologies can enable further pipeline expansion beyond products currently in development. In addition to CAR-T therapy for oncology, we can use our technologies to produce TCR-T and CAR-NK therapies for oncology. Beyond oncology, CAR-T therapy shows promise when applied to other therapeutic areas, potentially including autoimmune, infectious disease and allergy. Our technologies can also be used across other cell types, such as B-cells, HSCs and their derivatives and other T cells, such as regulatory T cells (Tregs). One example of a non-oncology application is P-HBB-101, an autologous gene therapy product candidate designed to deliver genetically modified HSCs to patients to potentially treat sickle cell disease.